Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02491073 · ClinicalTrials.gov registry record
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
A clinical trial, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- 71
- Enrollment target
NCT02491073: Completed study, sponsored by Sumitomo Pharma America.
NCT02491073 is a clinical trial that has completed, run by Sumitomo Pharma America. The registered enrollment target is 71 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02491073 has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if the blood tests used to measure free thyroid hormone levels are affected by a drug called eslicarbazepine acetate. To determine if eslicarbazepine acetate interferes with these blood tests, blood samples will be analysed so that researchers can compare different types of lab tests that measure these thyroid hormones. Half of the people who participate in this study will already be taking eslicarbazepine acetate either as a study drug or as a prescription (Part 1) and the other half will be people who do not take eslicarbazepine acetate (Part 2).
Interventions
- OTHER blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-03 |
What the finished NCT02491073 record still lists
NCT02491073 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 71 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which blood draw is the first listed.
NCT02491073 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02491073 about?
NCT02491073 is a clinical study titled "Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)". The purpose of this research study is to determine if the blood tests used to measure free thyroid hormone levels are affected by a drug called eslicarbazepine acetate. To determine if eslicarbazepine acetate interferes with these blood tests, blood samples will be analysed so that researchers can c...
What is the current status of trial NCT02491073?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2015-09. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02491073?
The interventions under investigation include: blood draw (OTHER).
Who is sponsoring clinical trial NCT02491073?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia